CN107540742B - Ctla-4变体 - Google Patents

Ctla-4变体 Download PDF

Info

Publication number
CN107540742B
CN107540742B CN201710735648.7A CN201710735648A CN107540742B CN 107540742 B CN107540742 B CN 107540742B CN 201710735648 A CN201710735648 A CN 201710735648A CN 107540742 B CN107540742 B CN 107540742B
Authority
CN
China
Prior art keywords
val
ser
thr
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710735648.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107540742A (zh
Inventor
R·敏特尔
J·杜思韦特
J·莫桑
M·鲍恩
S·拉斯特
C·普里韦曾特夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN107540742A publication Critical patent/CN107540742A/zh
Application granted granted Critical
Publication of CN107540742B publication Critical patent/CN107540742B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425Zeins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710735648.7A 2012-05-11 2013-03-11 Ctla-4变体 Active CN107540742B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
US61/645,686 2012-05-11
CN201380024763.3A CN104302309B (zh) 2012-05-11 2013-03-11 Ctla‑4变体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380024763.3A Division CN104302309B (zh) 2012-05-11 2013-03-11 Ctla‑4变体

Publications (2)

Publication Number Publication Date
CN107540742A CN107540742A (zh) 2018-01-05
CN107540742B true CN107540742B (zh) 2021-06-29

Family

ID=49551120

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710735648.7A Active CN107540742B (zh) 2012-05-11 2013-03-11 Ctla-4变体
CN201380024763.3A Active CN104302309B (zh) 2012-05-11 2013-03-11 Ctla‑4变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380024763.3A Active CN104302309B (zh) 2012-05-11 2013-03-11 Ctla‑4变体

Country Status (17)

Country Link
US (2) US9884902B2 (enExample)
EP (2) EP2863936A4 (enExample)
JP (1) JP6228971B2 (enExample)
KR (1) KR102133060B1 (enExample)
CN (2) CN107540742B (enExample)
AU (1) AU2013260172B2 (enExample)
BR (1) BR112014026718B1 (enExample)
CA (1) CA2868748C (enExample)
DK (1) DK3207938T3 (enExample)
ES (1) ES2777778T3 (enExample)
HK (1) HK1209644A1 (enExample)
HU (1) HUE048925T2 (enExample)
MX (2) MX355234B (enExample)
PL (1) PL3207938T3 (enExample)
RU (1) RU2671465C2 (enExample)
SG (2) SG10201609447XA (enExample)
WO (1) WO2013169338A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119857A1 (de) 1991-06-17 1992-12-24 Basf Lacke & Farben Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen
SG10201609447XA (en) * 2012-05-11 2017-01-27 Medimmune Llc Ctla-4 variants
ES2753150T3 (es) * 2012-06-29 2020-04-07 Bristol Myers Squibb Co Métodos para reducir la agregación de glucoproteínas
US9944689B2 (en) * 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
KR20160113268A (ko) * 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
EP3336100B1 (en) 2015-08-21 2021-01-13 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
EA201890729A1 (ru) * 2015-09-14 2018-09-28 Элпайн Имьюн Сайнс, Инк. Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR102813968B1 (ko) * 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112638419B (zh) * 2018-11-02 2022-06-24 北京伟德杰生物科技有限公司 修饰的ctla4及其使用方法
CN113645990B (zh) * 2019-04-10 2025-01-24 肯塔基大学研究基金会 改良的前列腺凋亡反应-4(par-4)多肽及其生产和使用方法
EP4090736A4 (en) * 2020-01-11 2024-02-21 Yale University COMPOSITIONS AND METHODS FOR THE TREATMENT, RELIEF AND/OR PREVENTION OF ILLNESSES OR DISORDERS ASSOCIATED WITH DNASE1 AND/OR DNASE1L3 DEFICIENCY
TWI896628B (zh) 2020-03-26 2025-09-11 美國凡德貝爾大學 針對嚴重急性呼吸症候群冠狀病毒2(SARS-CoV-2)之人單株抗體
EP4132965A2 (en) * 2020-04-06 2023-02-15 Lung Biotechnology PBC Modular synthetic receptors and methods of use
US20230167153A1 (en) 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
CN112661865A (zh) * 2020-12-31 2021-04-16 厚朴生物科技(苏州)有限公司 针对新型冠状病毒的疫苗以及其应用
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022359021A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved assay method for determining the potency of recombinant protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867583A (zh) * 2003-05-02 2006-11-22 赞科股份有限公司 优化的Fc变体及其产生方法
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0606217T4 (da) 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU3804397A (en) * 1996-06-14 1998-01-07 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP3029062A1 (en) * 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007007654A1 (ja) 2005-07-07 2007-01-18 Toshiba Lighting & Technology Corporation 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
PL2536745T3 (pl) * 2010-02-19 2017-01-31 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
SG10201609447XA (en) * 2012-05-11 2017-01-27 Medimmune Llc Ctla-4 variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867583A (zh) * 2003-05-02 2006-11-22 赞科股份有限公司 优化的Fc变体及其产生方法
WO2009058564A2 (en) * 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Differential effects of CTLA-4 substitutions on the binding of human CD80(B7-1) and CD86(B7-2);Morton等;《J Immunol》;pubmed;19961231;第156卷(第3期);第1047-1054页 *

Also Published As

Publication number Publication date
CN104302309A (zh) 2015-01-21
AU2013260172B2 (en) 2017-11-23
EP2863936A1 (en) 2015-04-29
MX385969B (es) 2025-03-18
KR102133060B1 (ko) 2020-07-10
CN104302309B (zh) 2017-07-28
PL3207938T3 (pl) 2020-07-13
US20150104450A1 (en) 2015-04-16
HK1209644A1 (en) 2016-04-08
RU2014150092A (ru) 2016-07-10
AU2013260172A1 (en) 2014-10-23
DK3207938T3 (da) 2020-03-16
EP3207938A2 (en) 2017-08-23
EP3207938A3 (en) 2017-11-01
MX2014013092A (es) 2015-03-03
HUE048925T2 (hu) 2020-09-28
RU2671465C2 (ru) 2018-10-31
CA2868748C (en) 2022-07-26
MX355234B (es) 2018-04-11
US20180208639A1 (en) 2018-07-26
EP2863936A4 (en) 2016-10-05
JP2015523328A (ja) 2015-08-13
CN107540742A (zh) 2018-01-05
JP6228971B2 (ja) 2017-11-08
BR112014026718B1 (pt) 2021-05-18
EP3207938B1 (en) 2019-12-25
WO2013169338A1 (en) 2013-11-14
BR112014026718A2 (pt) 2017-07-18
ES2777778T3 (es) 2020-08-06
US9884902B2 (en) 2018-02-06
SG10201609447XA (en) 2017-01-27
KR20150014443A (ko) 2015-02-06
SG11201405968SA (en) 2014-11-27
CA2868748A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
CN107540742B (zh) Ctla-4变体
US11365232B2 (en) Interleukin-2 fusion proteins and uses thereof
US9834589B2 (en) CD86 variants with improved affinity for CTLA-4
TWI671318B (zh) 介白素-2融合蛋白及其用途
EP2516458A1 (en) Tetravalent cd47-antibody constant region fusion protein for use in therapy
KR20160010466A (ko) Icosl에 대한 치료학적 표적 특이적 vnar 도메인의 단리
AU2007311608A1 (en) CTLA-4 Protein variants
KR20230025665A (ko) Cd3에 결합하는 항체
JP7535273B2 (ja) Cd80バリアントタンパク質とその使用
HK1241720B (en) Ctla-4 variants
HK1241720A1 (en) Ctla-4 variants
HK40091599A (zh) 免疫活化fc结构域结合分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant